PPD Selected as Member of New Medical Countermeasure Clinical Studies Network to Address Public Health Emergencies - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
PPD Selected as Member of New Medical Countermeasure Clinical Studies Network to Address Public Health Emergencies

Source: Company News Release

Pharmaceutical Product Development, LLC (PPD) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has chosen the company as one of a select group to design and conduct clinical studies needed to develop medical countermeasures – drugs, vaccines and diagnostic tests – that help protect health against bioterrorism, pandemic influenza and other public health emergencies.

BARDA, part of the U.S. Department of Health and Human Services (HHS), selected PPD as a contractor for the Medical Countermeasure Clinical Studies Network (MCM CSN). PPD will support BARDA and its development partners in planning, performing, monitoring and interpreting Phase I-IV clinical studies. Services include performing clinical studies that are required by the U.S. Food and Drug Administration for the approval of a product for human use, comparing the properties of multiple products or evaluating the potency of products stored in U.S. government stockpiles.

“PPD’s inclusion in this vital network highlights our industry-leading efforts to support government research and development programs through our robust, end-to-end clinical research services,” said Paul Colvin, PPD’s executive vice president of clinical development. “We are excited at the prospect of deploying our world-class scientific expertise, innovative solutions, cutting-edge technology, flexible resources and operational efficiencies to help protect public health and the nation’s health security.”

As a leading global contract research organization, having worked with all of the world’s top 50 pharmaceutical companies and conducting hundreds of clinical trials annually, PPD has provided a full range of study services on more than 1,300 government and public health projects in multiple indications, including infectious diseases, vaccines, biodefense, and autoimmune and asthma/allergic diseases.

PPD’s contract with BARDA is an indefinite-delivery, indefinite-quantity (IDIQ) agreement for clinical study services, with a minimum period of performance of two years and maximum period of performance of five years.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here